Musculoskeletal
Spinal Stenosis
12
Pipeline Programs↗
1
Active Trials↗
6
Companies Involved↗
Spinal Stenosis is an emerging landscape with 12 programs across 6 companies. The most active players are Citius Pharmaceuticals, Inc., Merck & Co., Quince Therapeutics S.p.A.. 5 therapies are approved with 1 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 13
Phase 2
No programs
Phase 31
Analysis
Trial Status
6
clinical trials
Completed2 · 33%
Unknown status2 · 33%
Withdrawn1 · 17%
Not yet recruiting1 · 17%
Clinical Trials
Trial Activity
6 trials
Misoprostol for Spinal Stenosis
Completed·—·N/A·NCT04611464·23 enrolled
The Clinical Effect of i-FACTOR® Versus Allograft in Non-instrumented Posterolateral Spondylodesis Operation in the Elderly With Spinal Stenosis Due to Degenerative Spondylolisthesis
Unknown status·—·Phase 3·NCT01618435·108 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)